Compare ADMA Biologics Inc (ADMA) vs Church & Dwight Co., Inc. (CHD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs Church & Dwight Co., Inc. — how do they compare? ADMA Biologics Inc trades at $9.88 (market cap $2.18B), while Church & Dwight Co., Inc. trades at $102.84 (market cap $24.50B). The key difference: Church & Dwight Co., Inc. is far larger — about 11.2× ADMA Biologics Inc's market cap, and Church & Dwight Co., Inc. pays a 1.19% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | CHD | |
|---|---|---|
Market Cap | $2.18B | $24.50B |
Sector | Health | Consumer Staples |
52-Week High | $20.38 | $105.26 |
52-Week Low | $7.60 | $81.60 |
Enterprise Value | $2.25B | $26.50B |
Dividend Yield | — | 1.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.90, down 1.59% today, with strong profitability metrics including 64.71% gross margin and 41.9% ROE. Technical indicators show a bullish trend with support at $9-10, though RSI levels suggest overbought conditions. Recent earnings show mixed results with Q4 2025 beating expectations but Q1 and Q2 2026 missing estimates. The stock faces significant legal headwinds with multiple securities fraud lawsuits filed against the company.
Despite strong fundamentals and bullish analyst consensus (88.9% buy ratings), ADMA faces substantial legal risks from ongoing securities litigation that could impact shareholder value. The company's solid profit margins and growth trajectory provide upside potential, but investors should carefully weigh litigation risks against fundamental strength.
Church & Dwight (CHD) trades at $103.24, slightly below the consensus price target of $103.57, with a modest 24-hour decline of 0.12%. The stock exhibits a bullish technical trend, supported by moving averages, while fundamentals show steady revenue growth to $6.20 billion in 2025 and a net income margin of 11.96%. Recent Q2 2026 earnings matched estimates with organic sales growth of 5.8%, prompting raised full-year guidance. Analyst sentiment is positive with 53% buy ratings, though valuation multiples like a P/E of 33.09 suggest premium pricing.
The outlook remains favorable due to strong brand performance and raised earnings guidance, but risks include elevated debt levels and competitive pressures in consumer staples. Institutional activity shows mixed positions, with some funds reducing stakes. The stock's upside is capped by high valuations, requiring sustained earnings growth to justify current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Church & Dwight Co., Inc.
Church & Dwight is the leading producer of baking soda in the world. Beyond baking soda, the products in its portfolio have vast category reach, including laundry products, cat litter, oral care, deodorant, and nasal care, all sold under the Arm & Hammer brand. Its mix also includes Xtra, Trojan, OxiClean, First Response, Nair, L'il Critters/Vitafusion, Orajel, and WaterPik, which together with Arm & Hammer constitute more than 80% of its annual sales and profits. In early 2019, the firm announced the addition of Flawless, which manufactures electric shaving products for women. At the end of 2020, the firm acquired Zicam, a leading brand in the cough/cold-shortening category. Church & Dwight derives more than 80% of its sales from its home market in the U.S.
Read more on CHD →
